Overview

* Vivos Q3 2025 revenue rises 76% yr/yr, driven by SCN acquisition

* Company's gross margin declines to 58% from 60% due to pricing discounts

* Operating expenses increase 74% due to SCN acquisition-related costs

Outlook

* Vivos expects near-term expenses to rise due to investments in SCN operations

* Company plans to expand sleep center model beyond Las Vegas

* Vivos anticipates seeing patients at new Michigan location by December

Result Drivers

* SCN ACQUISITION IMPACT - Vivos attributes 78% sequential revenue growth to the acquisition of The Sleep Center of Nevada

* STRATEGIC PIVOT - Co's shift from dental distribution to direct medical affiliations drives revenue increase

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 Net -$5.4

Income mln

Q3 Gross $3.94

Profit mln

Q3 -$4.73

Operatin mln

g Income

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"

* Wall Street's median 12-month price target for Vivos Therapeutics Inc ( VVOS ) is $6.50, about 62% above its November 18 closing price of $2.47

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)